3 days popular7 days popular1 month popular3 months popular

NIH study finds limited kidney benefit from more rigorous blood pressure treatment

Using two drugs was no more effective than a single drug in slowing disease progression in people with (ADPKD), according to two studies funded by the (). One of the studies also showed that rigorous slowed growth of kidney cysts, a marker of ADPKD, but had little effect on kidney function compared to standard .

Polycystic Kidney Disease]
This image shows kidneys affected by polycystic kidney disease.
Credit: New England Journal of Medicine 2010


HALT-PKD (tkNCT#) was supported by NIDDK under grants DK62408, DK62401, DK62410, DK62402, DK62411 and DK082230, with additional support from the NIH’s NCATS under grants RR000039, RR000585, RR000054, RR000051, RR023940, RR001032, RR025008, TR000454, RR024150, TR00135, RR025752, TR001064, RR025780, TR001082, RR025758, TR001102, RR033179, TR000001, RR024989 and TR000439 and the PKD Foundation. Study drugs were donated by Boehringer Ingelheim and Merck & Co., Inc.

1. Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease. November 15, 2014DOI: 10.1056/NEJMoa1402685

2. Angiotensin Blockade in Late Autosomal Dominant Polycystic Kidney Disease. November 15, 2014DOI: 10.1056/NEJMoa1402686

NIH/National Institute of Diabetes and Digestive and Kidney Diseases